To investigate the correlation between the angiotensin-converting enzyme(ACE) gene I/D polymorphism and prospective antihypertensive efficacy of ACE inhibitors (ACEI) in Xinjiang, Kazak, Uyghur patients with essential hypertension.

From November 2015 to April 2017, 394 patients with primary hypertension in the first Affiliated Hospital of Xinjiang Medical University were enrolled, including 191 Uyghur cases, 203 Kazak cases.The efficacy of ACE I/D genotype, ACEI drug efficacy, and adverse events were detected by the Gene Polymorphism Test Kit (PCR-fluorescence Probe Technique). The antihypertensive efficacy and adverse reactions of ACEI were analyzed.

Among the 394 patients, the number of normal sensitivity and high sensitivity to ACEI were 137 and 257 respectively.The frequency were 34.77%and 65.23%.Uyghur nationality were 33.51%(64/191) and 66.49%(127/191), Kazak patients were 35.96%(73/203) and 64.04%(130/203), respectively.There was no significant difference between the two groups(χ²=0.26, P>0.05). In 394 patients, the number of adverse drug reactions to ACEI was 81, and the frequency significantly increased by 20.56%, of which 19.37%(37/191) in Kazak and 21.67%(44/203) in Uyghur.There was no significant difference between the two nationalities in the adverse reactions of ACEI (χ²=0.32, P>0.05). Logistic regression analysis showed that ethnic differences in ACE I/D had no association with the efficacy of ACEI (OR=0.69, P>0.05).

There is no correlation between ACE gene I/D polymorphism in Xinjiang Kazak and Uygur patients with essential hypertension and the curative effect of ACEI.